Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants01:18

Anticoagulant Drugs: Vitamin K Antagonists and Direct Oral Anticoagulants

2.7K
Oral anticoagulants are vital tools in preventing and treating blood clotting disorders. This diverse class of medications can be categorized as vitamin K antagonists, exemplified by warfarin, and direct thrombin inhibitors (DTIs), such as dabigatran, as well as factor Xa inhibitors, including rivaroxaban.
Warfarin, a prominent vitamin K antagonist family member, exerts its effect by inhibiting the enzyme VKORC1 (vitamin K epoxide reductase complex 1). By hindering this enzyme, warfarin...
2.7K
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

2.3K
Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.3K
Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

459
Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
459
Extrinsic and Intrinsic Pathways of Hemostasis01:20

Extrinsic and Intrinsic Pathways of Hemostasis

15.0K
Blood clotting or coagulation involves extrinsic and intrinsic pathways, which ultimately merge into the common pathway, forming a fibrin clot.
The Extrinsic Pathway
The extrinsic pathway of coagulation is typically initiated by tissue damage that exposes blood to tissue factor (TF), a protein released by the damaged tissue cells outside the blood vessels—this interaction with TF triggers biochemical reactions involving specific clotting factors. The key player here is Factor VII, which...
15.0K
Disorders of Hemostasis01:24

Disorders of Hemostasis

2.7K
Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.
2.7K
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

10.0K
After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.0K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Rational design of a novel engineered factor X with chimeric activation peptide as bypassing agent for hemophilia.

Journal of thrombosis and haemostasis : JTH·2026
Same author

Blood Coagulation Factor IX: Structure, Function, and Regulation.

IUBMB life·2025
Same author

Basic regions of factor V and tissue factor pathway inhibitor mediate heavy chain and acidic region interactions on factor V revealed by tethered chemical cleavage.

Journal of thrombosis and haemostasis : JTH·2025
Same author

Acquired factor V inhibitor in a case of pediatric venous thrombosis.

Research and practice in thrombosis and haemostasis·2025
Same author

Packaging of supplemented urokinase into alpha granules of in vitro-grown megakaryocytes for targeted nascent clot lysis.

Blood advances·2024
Same author

Plasma growth factors maintain constitutive translation in platelets to regulate reactivity and thrombotic potential.

Blood advances·2024

Related Experiment Video

Updated: Mar 20, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K

Bioengineering factor Xa to treat bleeding.

Rodney M Camire1

  • 1The Children's Hospital of Philadelphia, The Raymond G. Perelman Center for Cellular and Molecular Therapeutics, and Division of Hematology, Department of Pediatrics, The University of Pennsylvania, Perelman School of Medicine, Philadelphia, PA 19104.

Thrombosis Research
|May 22, 2016
PubMed
Summary

Novel Factor Xa (FXa) variants offer a promising solution for controlling bleeding. These engineered FXa variants demonstrate safety and efficacy, particularly in hemophilia models, by localizing to injury sites.

Keywords:
bleedingfactor Xahemophiliahemostatic agentprocoagulantzymogen

More Related Videos

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Related Experiment Videos

Last Updated: Mar 20, 2026

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice
08:13

Tail Vein Transection Bleeding Model in Fully Anesthetized Hemophilia A Mice

Published on: September 30, 2021

7.7K
Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay
13:08

Measurement of Factor V Activity in Human Plasma Using a Microplate Coagulation Assay

Published on: September 9, 2012

19.5K
Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes
12:24

Helical Organization of Blood Coagulation Factor VIII on Lipid Nanotubes

Published on: June 3, 2014

12.8K

Area of Science:

  • Biochemistry and Molecular Biology
  • Hematology and Thrombosis

Background:

  • Clinical demand for rapid and safe bleeding control strategies in emergent situations.
  • Limitations of current hemostatic therapies.
  • Development of novel therapeutic agents targeting coagulation pathways.

Purpose of the Study:

  • To introduce and characterize novel zymogen-like Factor Xa (FXa) variants.
  • To evaluate the safety and efficacy of these FXa variants in preclinical models, specifically hemophilia.
  • To explore the potential of these variants as rapid pro-hemostatic agents for diverse bleeding conditions.

Main Methods:

  • Engineering of FXa variants with an amino acid change at the N-terminus of the heavy chain.
  • Assessment of biochemical properties, including resistance to plasma protease inhibitors and Factor Va (FVa) dependency.
  • In vivo characterization and efficacy testing in a hemophilia model system.

Main Results:

  • FXa variants exhibit altered conformational changes, leading to unique biochemical properties.
  • Variants demonstrate resistance to plasma protease inhibitors and low basal activity.
  • Activity is restored upon incorporation into the prothrombinase complex in a FVa-dependent manner, localizing pro-hemostasis to injury sites.

Conclusions:

  • Zymogen-like FXa variants are effective pro-hemostatic agents with potential for treating bleeding disorders.
  • FVa-dependent activity localization enhances efficacy and safety.
  • Preclinical data support the therapeutic potential of these FXa variants for hemophilia and other bleeding conditions.